Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27599314 | 0.98 | EPHX2 (0.54) | MEN1KMT2AEPHX2ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL1677813 | 0.98 | EPHX2 (0.50) | MEN1KMT2AEPHX2ALDH1A1TSHR | |
| SCHEMBL27617736 | 0.98 | EPHX2 (0.54) | MEN1KMT2AEPHX2ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL1677999 | 0.96 | EPHX2 (0.53) | MEN1KMT2AEPHX2ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL1677700 | 0.96 | EPHX2 (0.53) | MEN1KMT2AEPHX2ALDH1A1TSHR | |
| SCHEMBL1678510 | 0.94 | KMT2A (0.53) | MEN1KMT2AEPHX2ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL1678074 | 0.91 | EPHX2 (0.50) | MEN1KMT2AEPHX2ALDH1A1TSHR | |
| SCHEMBL1677910 | 0.86 | MEN1 (0.61) | MEN1KMT2AEPHX2ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1677389 | 0.85 | KMT2A (0.47) | MEN1KMT2AEPHX2ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL27539754 | 0.85 | KMT2A (0.59) | MEN1KMT2AEPHX2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1561749-B1 | TNF-Alpha production inhibitors for the treatment of autoimmune diseases | SANTEN PHARMACEUTICAL CO LTD (JP) | 2007-03-28 | — | — | EP | claimed |
| US-7923461-B2 | TNF-α production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-04-12 | — | — | US | disclosed |
| US-7741346-B2 | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| US-20100016380-A1 | TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20080161270-A1 | Angiogenesis inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-7345064-B2 | 5-(4-pyridyl)valeric acid N-[2-(1-adamantyl)ethyl]-N-pentylamide; Autoimmune diseases such as rheumatoid arthritis, allergy and diabetes | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-03-18 | — | — | US | disclosed |
| US-20060241155-A1 | 5-(4-pyridyl)valeric acid N-[2-(1-adamantyl)ethyl]-N-pentylamide; Autoimmune diseases such as rheumatoid arthritis, allergy and diabetes | SANTEN PHARMACEUTICAL, CO., LTD. (JP) | 2006-10-26 | — | — | US | disclosed |
| US-20050014800-A1 | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1457205-A1 | ANGIOGENESIS INHIBITOR | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241155-A1 | 5-(4-pyridyl)valeric acid N-[2-(1-adamantyl)ethyl]-N-pentylamide; Autoimmune diseases such as rheumatoid arthritis, allergy and diabetes | TNFRSF1A, FFAR4, NGFR | MEN1 3379/4885KMT2A 4142/4885EPHX2 1420/4885 |
| US-20080161270-A1 | Angiogenesis inhibitors | FLT4, KDR, FLT1 | MEN1 4587/4885KMT2A 4200/4885EPHX2 2354/4885 |
| US-20050014800-A1 | Angiogenesis inhibitor | FLT4, KDR, FLT1 | MEN1 4573/4885KMT2A 4173/4885EPHX2 2296/4885 |
| US-20100016380-A1 | TNF-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | MEN1 3108/4885KMT2A 4664/4885EPHX2 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.